lamotrigine and Disruptive, Impulse Control, and Conduct Disorders

lamotrigine has been researched along with Disruptive, Impulse Control, and Conduct Disorders in 5 studies

Disruptive, Impulse Control, and Conduct Disorders: Disorders whose essential features are the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the individual or to others. Individuals experience an increased sense of tension prior to the act and pleasure, gratification or release of tension at the time of committing the act.

Research

Studies (5)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Clinical Global Impressions-Improvement Scale (CGI-I)

The entire study for the subject will last 8 weeks. Every two weeks the subject will complete the CGI-I. The scale is a clinician-rated measure of overall disorder severity. Scores range from 1 (not at all improved) to 7 (very much improved). In each group, the number of people in each group who had a CGI-I score of 6 or 7 at Week 8 (indicating much or very much improved) will be presented. (NCT04792645)
Timeframe: 8 weeks

Hamilton Anxiety Rating Scale

A clinician-administered assessment of anxiety that will be assessed at all study visits. Score range: 0-56. Higher scores indicate more anxiety symptoms, with 0 being no symptoms of anxiety. Changes in scores from baseline to week 8 visit will be assessed. Positive values indicate an increase in score from baseline to week 8, whereas negative values indicate a decrease in score from baseline to week 8. (NCT04792645)
Timeframe: 8 weeks

Hamilton Depression Rating Scale

A clinician-administered assessment of depression that will be assessed at all study visits. Score range 0-58. Higher total scores indicate higher levels of depression, while a score of 0 would indicate no depressive symptoms. The change in score from baseline to Week 8 is reported. Positive values indicate an increase in score from baseline to Week 8, whereas negative values indicate a decrease in score from baseline to Week 8. (NCT04792645)
Timeframe: 8 weeks

Massachusetts General Hospital Hairpulling (Skin Picking) Scale

Brief, self-report scale for assessing repetitive hairpulling (or skin picking). Because of a lack of an identical scale for skin-picking behavior, this scale was modified for skin picking for individuals with SPD to keep the outcome measure consistent across disorders. Seven individual items, rated for severity from 0 to 4, assess urges to pull (pick), actual pulling (picking), perceived control, and associated distress (range 0-28). The change in scores from baseline to after 8 weeks is reported. Negative values indicate a decrease in score from baseline to 8 weeks, while positive values indicate an increase in score from baseline to 8 weeks. (NCT04792645)
Timeframe: 8 weeks

NIMH Symptom Severity Scale (for TTM or Skin Picking)

The primary efficacy measure will be the change in hair pulling or skin picking frequency and urges to pull hair or pick skin for the past week as indicated by change in total score. The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH Symptom Severity Scale. The change in scores from baseline to after 8 weeks will be assessed. The scale itself assesses severity of trichotillomania or skin picking symptom, with higher scores indicating greater trichotillomania or skin picking severity. Score range: 0-20. (NCT04792645)
Timeframe: The primary efficacy end points will be the change in these measures from baseline to week 8.

Sheehan Disability Scale

Subjects will complete the Sheehan Disability Scale (SDS) at all visits. The SDS is a self-report measure of functional impairment. Scores range from 0-30, with higher scores indicating greater functional impairment. The average change in score from baseline to Week 8 will be reported. Negative values indicate a decrease in score from baseline to Week 8, while positive values indicate an increase in score. (NCT04792645)
Timeframe: 8 weeks

Skin Picking Symptom Assessment Scale

The entire study lasts 8 weeks. Every two weeks subjects will take the Skin Picking Symptom Assessment Scale (SP-SAS). The scale itself assesses severity of skin-picking symptoms. The SP-SAS score ranges from 0 to 48, with 0 being no symptoms and 48 being the most severe. The average change in score from baseline to Week 8 will be reported for both groups. A positive value indicates an increase in score from baseline to week 8, whereas a negative value indicates a decrease in score from baseline to week 8. (NCT04792645)
Timeframe: 8 weeks

Trials

2 trials available for lamotrigine and Disruptive, Impulse Control, and Conduct Disorders

Other Studies

3 other studies available for lamotrigine and Disruptive, Impulse Control, and Conduct Disorders